Curaleaf Holdings (CURLF) Income towards Parent Company (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Income towards Parent Company of -$293000.0 for Q1 2026, up 97.13% year-on-year from -$148636.3 in Q1 2025, and up 98.13% on a QoQ basis from -$15.7 million in Q4 2025.
Curaleaf Holdings (CURLF) Income towards Parent Company (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Income towards Parent Company for 8 consecutive years, with -$293000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income towards Parent Company rose 97.13% year-over-year to -$293000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.1 million (changed 0.31% YoY) and the FY2025 annual result came in at -$26.2 million, down 152.45% from the prior year.
- Income towards Parent Company climbed to -$293000.0 in Q1 2026 per CURLF's latest filing, from -$15.7 million in the prior quarter.
- Over the last five years, Income towards Parent Company for CURLF reached as high as $64.5 million in Q1 2022 and fell as low as -$8.0 billion in Q4 2023.
- A 5-year average of -$477.8 million and a median of -$7.9 million in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company tumbled 9157.22% — and 2024, when it jumped 106.25%.
- Year by year, Income towards Parent Company stood at -$86.4 million in 2022, then slumped by 9157.22% to -$8.0 billion in 2023, then surged by 99.86% to -$11.3 million in 2024, then plunged by 38.46% to -$15.7 million in 2025, then soared by 98.13% to -$293000.0 in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$293000.0, -$15.7 million, and -$2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Curaleaf Holdings | 6.95 Bn | 6.95 Bn | 157.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -293,000.00 |
| Dec 31, 2025 | -15.66 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | -3.00 Mn |
| Mar 31, 2025 | -10.19 Mn |
| Dec 31, 2024 | -11.31 Mn |
| Sep 30, 2024 | 1.62 Mn |
| Jun 30, 2024 | -1.28 Mn |
| Mar 31, 2024 | 567,000.00 |
| Dec 31, 2023 | -8.00 Bn |
| Sep 30, 2023 | -25.92 Mn |
| Jun 30, 2023 | -7.90 Mn |
| Mar 31, 2023 | -12.59 Mn |
| Dec 31, 2022 | -86.37 Mn |
| Sep 30, 2022 | -12.73 Mn |
| Jun 30, 2022 | -4.50 Mn |
| Mar 31, 2022 | 64.53 Mn |
| Dec 31, 2021 | -5.24 Mn |
| Sep 30, 2021 | 62.95 Mn |
| Jun 30, 2021 | 76.97 Mn |